{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:56:19Z","timestamp":1777532179755,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM127558"],"award-info":[{"award-number":["R01GM127558"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R01AI120749"],"award-info":[{"award-number":["R01AI120749"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jconrel.2023.04.037","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T13:14:02Z","timestamp":1682774042000},"page":"116-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates"],"prefix":"10.1016","volume":"358","author":[{"given":"Fernanda P.","family":"Pons-Faudoa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Di Trani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Capuani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathanael","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharti","family":"Nehete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Niles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn A.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kezar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lane R.","family":"Bushman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrine Ying Xuan","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Ittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod N.","family":"Nehete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto C.","family":"Arduino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan E.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Grattoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.04.037_bb0005","series-title":"Miles to Go: Global AIDS Update 2018","first-page":"59","author":"UNAIDS","year":"2018"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0010","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2018.08.010","article-title":"Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis","volume":"286","author":"Chua","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0030","article-title":"Ultra-long-acting refillable nanofluidic implant confers full protection against SHIV infection in non-human primates","author":"Pons-Faudoa","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2019.05.037","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis","volume":"306","author":"Pons-Faudoa","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10544-019-0389-6","article-title":"Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases","volume":"21","author":"Pons-Faudoa","year":"2019","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0045","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000470","article-title":"Antiretroviral implants for treatment and prevention of HIV infection","volume":"13","author":"Flexner","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052880","article-title":"CAPRISA 018: a phase I\/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women","volume":"12","author":"Gengiah","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0055","doi-asserted-by":"crossref","first-page":"119623","DOI":"10.1016\/j.ijpharm.2020.119623","article-title":"Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications","volume":"587","author":"Sizovs","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0060","doi-asserted-by":"crossref","first-page":"2000163","DOI":"10.1002\/adtp.202000163","article-title":"Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates","volume":"4","author":"Pons-Faudoa","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0065","article-title":"Extending drug release from implants via transcutaneous refilling with solid therapeutics","volume":"2100214","author":"Di Trani","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0070","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/pharmaceutics12100981","article-title":"Viral load reduction in SHIV-positive nonhuman primates via long-acting subcutaneous tenofovir alafenamide fumarate release from a nanofluidic implant","volume":"12","author":"Pons-Faudoa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0075","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01893-19","article-title":"A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques","volume":"64","author":"Su","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0080","series-title":"WHO Expert Committee on Biological Standardization: Sixty-Sixth Report","volume":"999","author":"Standardization, W. H. O. E. C. o. B. & Organization, W. H","year":"2016"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0085","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2818.1993.tb03312.x","article-title":"Fluorescence photobleaching recovery in the confocal scanning light microscope","volume":"169","author":"Blonk","year":"1993","journal-title":"J. Microsc."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0090","article-title":"Potentiating antitumor efficacy through radiation and sustained Intratumoral delivery of anti-CD40 and anti-PDL1","author":"Liu","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0095","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nmeth.4391","article-title":"histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data","volume":"14","author":"Schapiro","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpba.2011.05.039","article-title":"Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC\u2013MS\/MS detection","volume":"56","author":"Bushman","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0105","series-title":"Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who have Sex with Men","author":"Anderson","year":"2012"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0110","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jid.2020.07.017","article-title":"The multiple roles of urocanic acid in health and disease","volume":"141","author":"Hart","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/1523-1747.ep12499855","article-title":"Inhibition of skin allograft rejection and acute graft-versus-host disease by cis-urocanic acid","volume":"98","author":"Gruner","year":"1992","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0120","article-title":"Advanced strategies to thwart foreign body response to implantable devices","volume":"e10300","author":"Capuani","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0125","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41577-019-0162-3","article-title":"T cells and the skin: from protective immunity to inflammatory skin disorders","volume":"19","author":"Ho","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0130","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajp.22281","article-title":"Why primate models matter","volume":"76","author":"Phillips","year":"2014","journal-title":"Am. J. Primatol."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.12258","article-title":"Immunology studies in non-human primate models of tuberculosis","volume":"264","author":"Flynn","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0140","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/193229680800200504","article-title":"A review of the foreign-body response to subcutaneously-implanted devices: the role of macrophages and cytokines in biofouling and fibrosis","volume":"2","author":"Ward","year":"2008","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0145","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmat4866","article-title":"Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates","volume":"16","author":"Doloff","year":"2017","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/ars.2010.3241","article-title":"Nonhuman primate models of human immunology","volume":"14","author":"Messaoudi","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nri977","article-title":"A road less travelled: large animal models in immunological research","volume":"3","author":"Hein","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0160","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0167-5699(92)90005-R","article-title":"Immunosuppression by ultraviolet B radiation: initiation by urocanic acid","volume":"13","author":"Noonan","year":"1992","journal-title":"Immunol. Today"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0165","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/aid.2021.0028","article-title":"Tenofovir alafenamide for HIV prevention: review of the proceedings from the gates foundation long-acting TAF product development meeting","volume":"37","author":"Romano","year":"2021","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0170","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/infdis\/jiz383","article-title":"Efficacy of oral tenofovir alafenamide\/emtricitabine combination or single-agent tenofovir alafenamide against vaginal simian human immunodeficiency virus infection in macaques","volume":"220","author":"Massud","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0175","series-title":"Biodegradable TAF Implants Protect 6 of 6 Macaques From Vaginal SHIV, HIV 4RP","author":"Mascolini","year":"2021"},{"key":"10.1016\/j.jconrel.2023.04.037_bb0180","article-title":"Opportunities and challenges in the diagnostic utility of dermal interstitial fluid","volume":"1-15","author":"Friedel","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000083706","article-title":"Dermal capillary clearance: physiology and modeling","volume":"18","author":"Kretsos","year":"2005","journal-title":"Skin Pharmacol. Physiol."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0190","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00018-014-1561-z","article-title":"Pathogenesis of skin ulcers: lessons from the mycobacterium ulcerans and Leishmania spp. pathogens","volume":"71","author":"Guenin-Mac\u00e9","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jconrel.2023.04.037_bb0195","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/pharmaceutics11070315","article-title":"Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP)","volume":"11","author":"Johnson","year":"2019","journal-title":"Pharmaceutics"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923002870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923002870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T17:52:13Z","timestamp":1764870733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923002870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"alternative-id":["S0168365923002870"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.037","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}